We are a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system – but most importantly to save lives.
Ticker:
DYAI
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Florida
Company HQ Country:
United States
Year Founded:
1979
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
N/A
Development Phase of Primary Product:
Discovery
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
